coronary artery disease

Mitiperstat is a potent myeloperoxidase (MPO) inhibitor that is effective in preventing cardiovascular diseases such as heart failure and coronary artery disease.

Arbutamine (GP 21213) is a novel potent non-selective beta-adrenoceptor agonist with alpha-1-sympathomimetic activity.Arbutamine promotes cardiac stress and increases heart rate, cardiac contractility.Arbutamine can be used to study cardiac stress and coronary artery disease

(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide is an Apelin receptor agonist with an EC50 for Apelin receptors of 0.012 µM.(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5- methylpyrimidin-2-yl)butane-2-sulfonamide is used in the treatment of heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke and myocardial infarction.

GP2-114 is a catecholamine motility mimetic that produces current-dependent cardiovascular effects when administered via transdermal iontophoresis and can be used to study coronary artery disease (CAD).

Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling. Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.

Gue1654 is a selective OXE-R inhibitor that attenuates coronary artery ligation-induced ischemic myocardial injury and cardiomyocyte oxygen glucose deprivation-induced injury in mice through activation of BCAT1.Gue1654 inhibits OXE-R-inhibited protein kinase C-ε (PKC-ε) nuclear factor κB (NF-κB) signaling and apoptosis in cardiomyocytes. Gue1654 can be used to study cardiovascular disease.

Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.

Indecainide (Ricainid) is a novel antiarrhythmic compound that is carcinogenic and can be used to study chronic stable ventricular arrhythmias secondary to coronary artery disease or cardiomyopathy.

Tea polyphenol, also called green tea extract, are a mixture of chemical compounds, such as flavanoids and tannins, found naturally in tea. Polyphenols are powerful antioxidants, which can reduce the risk of developing coronary artery disease and a number

Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others

Vicagrel is an effective, orally active antiplatelet compound that enhances the inhibitory effect of aspirin on platelet aggregation and thrombosis in rodents by irreversibly inhibiting P2Y12 receptors and reducing metabolic inactivation. Viagrel can be used to treat blood clots in coronary artery disease, peripheral vascular disease and cerebrovascular disease.

Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling. Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.

(R)-Clopidogrel bisulfate (Clopidogrel Related Compound C) is an isomer of Clopidogrel. Clopidogrel is a P2Y12 receptor antagonist that reduces platelet aggregation, used to prevent thrombotic events in coronary artery disease, peripheral artery disease, and cerebrovascular disease.

Barucainide dihydrochloride is an IB antiarrhythmic compound that has been evaluated in patients with coronary artery disease.

Barucainide HCl, a class IB antiarrhythmic compound, was evaluated in patients with coronary artery disease.

Perindopril (S-9490) is a long-acting ACE inhibitor effective for 24 hours, primarily utilized in the management of high blood pressure, heart failure, or stable coronary artery disease. Available as perindopril arginine (with trade names such as Coversyl and Coversum) or perindopril erbumine (known as Aceon), both formulations are regarded therapeutically equivalent, according to the Australian Government's Pharmaceutical Benefits Scheme—meaning they can be interchanged without clinical effect differences, though their dosing may vary due to distinct molecular weights. Notably, perindopril ranks among the most frequently prescribed ACE inhibitors, thanks to its extensive evidence base supporting its use in patients with hypertension, type 2 diabetes, coronary heart disease, and chronic heart failure. This review highlights perindopril's organoprotective benefits that extend beyond its capacity to lower blood pressure.

Apabetalone (RVX000222) , an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.

Batifiban, a glycoprotein IIb/IIIa antagonist, is used potentially for the treatment of coronary artery disease.

AZD2716 is an effective selective phospholipase A2 inhibitor for the treatment of coronary artery and cardiovascular disease.

Lysophosphatidylcholine 18:2 is a mouse metabolite functionally related to linoleic acid.18:2 LysoPC is a major component of oxidized low-density lipoproteins (LDLs), and low plasma levels of LPC 18:2 have been associated with metabolic disorders such as impaired glucose tolerance, insulin resistance, type 2 diabetes, and coronary artery disease.1-Linoleoyl 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC is also a substrate for the generation of lysophosphatidic acid (LPA) from Autotaxin (LysoPLD), which plays an important role in cell motility.

Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.